sipuleucel-T

A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND Sipuleucel-T is a US Food and Drug Administration-approved immunotherapy for asymptomatic or minimally symptomatic… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2011
2011
PURPOSE Sipuleucel-T, an autologous cellular immunotherapy, was investigated in a randomized, double-blind, controlled trial to… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2011
Review
2011
In April 2010, sipuleucel-T became the first anticancer vaccine approved by the United States Food and Drug Administration… (More)
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
Is this relevant?
2011
2011
INTRODUCTION Among the leading causes of cancerrelated deaths, prostate cancer is second to lung cancer, but it is the most… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of… (More)
  • figure 1
  • table 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Sipuleucel-T is an investigational active cellular immunotherapy product designed to stimulate an immune response… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Review
2006
Review
2006
Sipuleucel-T (Provenge; APC8015; Dendreon Corp, WA, USA) is a novel immunotherapeutic cellular product, which includes autologous… (More)
Is this relevant?